Published in Cancer Weekly, September 13th, 2005
"Young-adult patients with acute lymphoblastic leukemia represent a unique epidemiologic subgroup in that therapy may be provided by either adult or pediatric oncologists. There seem to be no differences in presenting clinical features, immunophenotypic characteristics, or cytogenetic abnormalities for young-adult ALL patients treated on pediatric or adult protocols with the exception of median age (16 - pediatric trials versus 19 - adult trials)," scientists in the United States reported.
"There is no evidence to suggest that age within the 16-21...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.